The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with the Indian Council of Medical Research, the Hyderabad-based company said in a statement.
The massive inoculation drive against the Covid-19 disease in this phase was lead from the front on the day as Prime Minister Narendra Modi took the jab at AIIMS here earlier.
Dr Krishna M Ella, CMD and Suchitra Ella, joint managing director, Bharat Biotech International will receive the award on February 22, during the inaugural event of BioAsia 2021.
Medical freezers, which maintain 20°C are also being deployed for diluents and ice packs needed for the last mile delivery in the Covid vaccination drive.
Under the terms of the agreement, Ocugen will have the US rights to the vaccine candidate and will be responsible for clinical development, regulatory approval (including emergency use authorisation (EUA)) and commercialisation for the US market.
India had earlier in January approved two vaccines -- Oxford's Covishield manufactured by SII and Bharat Biotech's Covaxin -- for restricted emergency use.
Covaxin is India's totally indigenous COVID-19 vaccine developed in collaboration with the Indian Council of Medical Research and National Institute of Virology.
This is India's first and only phase-3 efficacy study for a Covid-19 vaccine, and the largest phase-3 efficacy trial ever conducted for any vaccine in the country.
The company was given a fresh letter of comfort recently for supplying another 45 lakh doses of Covaxin. The doses will be dispatched as when the Ministry places orders with the company